Established in 2010 and listed on KOSDAQ in 2017, our company is a bio venture firm headquartered in Gangnam, Seoul, with factories and a research center in Chuncheon. Our main product, the oral cholera vaccine ‘Euvichol-Plus,’ received WHO PQ approval in 2017 and is supplied globally through UNICEF. Utilizing our conjugate protein platform technology, we are developing typhoid fever, meningococcal (4- and 5-valent), and pneumococcal (15-valent) conjugate vaccines. Additionally, based on our new adjuvant platform, we are developing premium vaccines targeting advanced markets, including those for RSV, shingles, and JEV, as well as vaccines against emerging infectious diseases. With state-of-the-art GMP facilities and experienced professionals, we provide customized CRMO services for biopharmaceutical development and production, supplying non-clinical samples, clinical drugs, and commercial products in compliance with international regulatory standards.
moreEXHIBIT
COMPANY INTRODUCTION
Established in 2010 and listed on KOSDAQ in 2017, our company is a bio venture firm headquartered in Gangnam, Seoul, with factories and a research center in Chuncheon. Our main product, the oral cholera vaccine ‘Euvichol-Plus,’ received WHO PQ approval in 2017 and is supplied globally through UNICEF. Utilizing our conjugate protein platform technology, we are developing typhoid fever, meningococcal (4- and 5-valent), and pneumococcal (15-valent) conjugate vaccines. Additionally, based on our new adjuvant platform, we are developing premium vaccines targeting advanced markets, including those for RSV, shingles, and JEV, as well as vaccines against emerging infectious diseases. With state-of-the-art GMP facilities and experienced professionals, we provide customized CRMO services for biopharmaceutical development and production, supplying non-clinical samples, clinical drugs, and commercial products in compliance with international regulatory standards.
